

Keisuke Miyake

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/136011/publications.pdf>

Version: 2024-02-01

27
papers

381
citations

840119

11
h-index

794141

19
g-index

27
all docs

27
docs citations

27
times ranked

653
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET. <i>Nuclear Medicine Communications</i> , 2022, 43, 270-274.	0.5	3
2	Correlation of ^{11}C -[methyl- ^{11}C]-thiothymidine PET with Gd-enhanced and FLAIR MRI in patients with newly diagnosed glioma. <i>EJNMMI Research</i> , 2021, 11, 42.	1.1	1
3	Opening the Palatovaginal Canal to Maximize Anterior Sphenoidotomy in Endoscopic Endonasal Surgery. <i>Laryngoscope</i> , 2021, 131, 2461-2464.	1.1	1
4	Increased Uptake of 18F-THK5351 in Glioblastoma But Not in Primary Central Nervous System Lymphoma. <i>Clinical Nuclear Medicine</i> , 2021, 46, 772-773.	0.7	5
5	Correlation of ^{11}C -[methyl- ^{11}C]-thiothymidine PET with Ki-67 immunohistochemistry separately in patients with newly diagnosed and recurrent gliomas. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 1322-1327.	0.5	0
6	Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas. <i>EJNMMI Research</i> , 2021, 11, 67.	1.1	1
7	Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa172.	0.4	3
8	Fractal analysis of ^{11}C -methionine PET in patients with newly diagnosed glioma. <i>EJNMMI Physics</i> , 2021, 8, 76.	1.3	3
9	Temporal and spatial changes in reactive astrogliosis examined by 18F-THK5351 positron emission tomography in a patient with severe traumatic brain injury. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 26.	0.6	4
10	A rare case of BRAF V600E-mutated epithelioid glioblastoma with a sarcomatous component. <i>Pathology International</i> , 2020, 70, 166-170.	0.6	5
11	Diagnostic value of PET/CT with ^{11}C -methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification. <i>EJNMMI Research</i> , 2020, 10, 44.	1.1	15
12	A Rare Case of Postoperative Symptomatic Cyst Formation After Resection of a Large Convexity Meningioma. <i>World Neurosurgery</i> , 2019, 127, 160-164.	0.7	0
13	NI-15 THE USEFULNESS OF PET IMAGING IN MOLECULAR DIAGNOSIS OF GLIOMA. <i>Neuro-Oncology Advances</i> , 2019, 1, ii28-ii28.	0.4	0
14	ET-04 MOLECULAR TARGETED THERAPY AGAINST (PRO)RENIN RECEPTOR FOR GLIOBLASTOMA. <i>Neuro-Oncology Advances</i> , 2019, 1, ii8-ii9.	0.4	0
15	Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab. <i>Cancer Science</i> , 2019, 110, 499-508.	1.7	58
16	Association between dexmedetomidine use and neurological outcomes in aneurysmal subarachnoid hemorrhage patients: A retrospective observational study. <i>Journal of Critical Care</i> , 2018, 44, 111-116.	1.0	15
17	Correlation of ^{11}C -[methyl- ^{11}C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas. <i>Annals of Nuclear Medicine</i> , 2018, 32, 634-641.	1.2	2
18	Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. <i>Brain Tumor Pathology</i> , 2017, 34, 62-77.	1.1	82

#	ARTICLE	IF	CITATIONS
19	Intratumoral heterogeneity of 18F-FLT uptake predicts proliferation and survival in patients with newly diagnosed gliomas. <i>Annals of Nuclear Medicine</i> , 2017, 31, 46-52.	1.2	18
20	“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab. <i>Oncotarget</i> , 2017, 8, 103890-103899.	0.8	14
21	Diagnostic Performance and Safety of Positron Emission Tomography Using F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2017, 5, 10-21.	0.1	28
22	Usefulness of positron emission tomographic studies for gliomas. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 396-408.	1.0	15
23	Histopathological investigation of glioblastomas resected under bevacizumab treatment. <i>Oncotarget</i> , 2016, 7, 52423-52435.	0.8	42
24	ANGI-13 HISTOPATHOLOGICAL INVESTIGATION OF GLIOBLASTOMAS RESECTED UNDER CONTROL OF NEOADJUVANT BEVACIZUMAB. <i>Neuro-Oncology</i> , 2015, 17, v43.4-v44.	0.6	0
25	Comparison of 4- ¹¹ C-methyl-thiothymidine (11C-4DST) and 3-deoxy-3-[¹⁸ F]fluorothymidine (18F-FLT) PET/CT in human brain glioma imaging. <i>EJNMMI Research</i> , 2015, 5, 7.	1.1	16
26	3-Deoxy-3-[¹⁸ F]-fluorothymidine ([¹⁸ F]-FLT) transport in newly diagnosed glioma: correlation with nucleoside transporter expression, vascularization, and blood-brain barrier permeability. <i>Brain Tumor Pathology</i> , 2013, 30, 215-223.	1.1	13
27	Usefulness of FDG, MET and FLT-PET Studies for the Management of Human Gliomas. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-11.	3.0	37